Search research articles
Contact Us
Filters
Showing results (111-120 of 173) with videos related to
Page
of 18
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 7, 2024
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer
Rachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, et al.
Cancer Medicine
|
September 26, 2024
Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer
Kosei Hasegawa, Shunji Takahashi, Kimio Ushijima, et al.
Gynecologic Oncology
|
June 4, 2024
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Giorgio Valabrega, Bhavana Pothuri, Ana Oaknin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 18, 2024
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics
Stanislas Quesada, Frédérique Penault-Llorca, Xavier Matias-Guiu, et al.
Autophagy
|
May 14, 2020
The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells
Pau Muñoz-Guardiola, Josefina Casas, Elisabet Megías-Roda, et al.
The Lancet. Oncology
|
March 17, 2022
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Rebecca Kristeleit, Alla Lisyanskaya, Alexander Fedenko, et al.
Gynecologic Oncology
|
October 23, 2022
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma
David M O'Malley, Amit M Oza, Domenica Lorusso, et al.
Virchows Archiv : an International Journal of Pathology
|
May 5, 2023
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023
David Cibula, Maria Rosaria Raspollini, François Planchamp, et al.
Gynecologic Oncology
|
August 23, 2016
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Gynecologic Oncology
|
March 12, 2019
Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer
Isidre Felip, Cristian Pablo Moiola, Cristina Megino-Luque, et al.
Page
of 18
Search research articles
Search
Showing results (111-120 of 173) with videos related to
Sort By:
Page
of 18
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 7, 2024
GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer
Rachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen, et al.
Cancer Medicine
|
September 26, 2024
Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer
Kosei Hasegawa, Shunji Takahashi, Kimio Ushijima, et al.
Gynecologic Oncology
|
June 4, 2024
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Giorgio Valabrega, Bhavana Pothuri, Ana Oaknin, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 18, 2024
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics
Stanislas Quesada, Frédérique Penault-Llorca, Xavier Matias-Guiu, et al.
Autophagy
|
May 14, 2020
The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells
Pau Muñoz-Guardiola, Josefina Casas, Elisabet Megías-Roda, et al.
The Lancet. Oncology
|
March 17, 2022
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
Rebecca Kristeleit, Alla Lisyanskaya, Alexander Fedenko, et al.
Gynecologic Oncology
|
October 23, 2022
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma
David M O'Malley, Amit M Oza, Domenica Lorusso, et al.
Virchows Archiv : an International Journal of Pathology
|
May 5, 2023
ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023
David Cibula, Maria Rosaria Raspollini, François Planchamp, et al.
Gynecologic Oncology
|
August 23, 2016
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2
Bradley J Monk, Andrés Poveda, Ignace Vergote, et al.
Gynecologic Oncology
|
March 12, 2019
Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer
Isidre Felip, Cristian Pablo Moiola, Cristina Megino-Luque, et al.
Page
of 18